期刊文献+

脂蛋白相关磷脂酶A2基因I198T和V279F多态性与冠状动脉粥样硬化病变程度的相关性 被引量:8

Association of I198T and A379V polymorphisms in lipoprotein-associated phospholipase A2 with extent of coronary atherosclerosis
下载PDF
导出
摘要 目的 :探讨脂蛋白相关磷脂酶A2(Lp-PLA2)基因I198T、V279F多态性与冠状动脉粥样硬化病变严重程度和稳定性的相关性。方法:纳入268例冠状动脉粥样硬化患者及113例冠脉造影完全正常者,应用DNA测序仪检测Lp-PLA2基因I198T和V279F多态性,并进行统计学分析。结果:按照Gensini积分及冠心病临床分型,所分亚组的I198T和V279F基因型频率及其等位基因频率与对照组无差异;单支冠脉病变者IT+TT基因型和VF+FF基因型及其等位基因F频率高于对照组,而多支病变者则与对照组无差异。亦未发现I198T和V279F不同基因型在血脂水平及高血压、糖尿病患者比例上有差别。结论:未能发现Lp-PLA2基因I198T和V279F变异与冠状动脉粥样硬化病变严重程度和稳定性的显著相关性。 Objective:To investigate whether I198T and A379V polymorphisms in lipoprotein-associated phospholipase A2 (Lp- PLA2)correlate with severity and stability of coronary atherosclerosis. Methods:V279F and A379V polymorphisms in Lp-PLA2 gene of 268 patients with coronary atherosclerosis and 113 controls without coronary atherosclerosis were genotyped by DNA sequencing instrument and analyzed by statistical methods. Results:Stratified by Gensini score and clinical types, no significant associations were observed between subgroups and the controls in I198T and V279F genotypes and allele frequencies. As for subgroups stratified by numbers of diseased coronary branches,only subjects with one diseased coronary branches carried higher frequencies of genotype IT+ TF,VF+FF and F allele as compared to the controls. No associations were observed between patients with multi-vessel lesions and controls in I198T and V279F. In the further analysis of risk factors,blood fat levels and proportions of diabetes and hypertension patients in subjects carrying IT+TT and VF+VV genotypes showed no difference with II and VV genotypes. Conclusion:No associations existed between I198T and V279F polymorphisms in Lp-PLA2 and the severity and stability of coronary atherosclerosis.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2015年第3期380-384,共5页 Journal of Nanjing Medical University(Natural Sciences)
基金 江苏省自然科学基金资助项目(BK2009450) 江苏省社会发展基金资助项目(BE2011804)
关键词 脂蛋白相关性磷脂酶A2 I198T V279F 冠状动脉粥样硬化 冠心病 lipoprotein-associated phospholipase A2 I198T V279F coronary arteriosclerosis coronary heart disease
  • 相关文献

参考文献19

  • 1Berman JP, Farkouh ME, Rosenson RS. Emerging anti-in- flammatory drugs for atherosclerosis[J]. Expert Opin E-merg Drugs, 2013,18(2) : 193-205.
  • 2杨玉娇,刘正霞,吴玉呈,周萍,刘莹,鲁翔.冠心病患者血清细胞因子水平及临床意义[J].南京医科大学学报(自然科学版),2014,34(6):755-760. 被引量:10
  • 3Zheng GH, Chen HY,Xiong SQ,et al. Lipoprotein-associ- ated phospholipase A2 gene V279F polymorphisms and coronary heart disease : a meta-analysis[J]. Mol Biol Rep, 2011,38 (6) : 4089-4099.
  • 4Cai A,Zheng D,Qiu R,et al. Lipoprotein-associated phos- pholipase A2(Lp-PLA(2))a novel and promising biomark- erfor cardiovascular risks assessment[J]. Dis Markers, 2013,34(5) :323-331.
  • 5Ninio E,Tregouet D,Carrier JL,et al. Platelet-activating factor-aeetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease[J]. Hum Mol Genet,2004,13 (13):1341-1351.
  • 6Xu L,Zhou J,Huang S,et al. An association study be- tween genetic polymorphisms related to lipoprotein-asso- ciated phospholipase A(2)and coronary heart disease[J]. Exp Ther Med,2013,5(3):742-750.
  • 7Li L,Qi L,Lv N,et al. Association between lipoprotein- associated phospholipase A2 gene polymorphism and coronary artery disease in the Chinese Han population [J]. Ann Hum Genet,2011,75(5):605-611.
  • 8Liu J,Wang W,Qi Y,et al. Association between the lipoprotein-associated phospholipase A2 activity and the progression of subclinical atherosclerosis [J]. J Atheroscler Thromb, 2014,21 (6) : 532-542.
  • 9Jabor B, Choi H,Ruel I,et al. Lipoprotein-associated phospholipase A(2)(Lp-PLA(2))in acute coronary syn- drome:relationship with low-density lipoprotein choles- terol[Jl. Can J Cardiol,2013, 29(12):1679-1686.
  • 10Charniot JC, Khani-Bittar R, Albertini JP, et al. Interpre- tation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease,comorbidities, extension of atherosclerosis and treatments[J]. Int J Cardiol,2013,168 (1):132-138.

二级参考文献15

  • 1Krychtiuk KA,Kastl SP,Speidl WS,et al. Inflammation and coagulation in atherosclerosis [J]. Hamostaseologie, 2013,33(4) :269-282.
  • 2Badimon L,Romero JC,Cubedo J,et al. Circulating biomarkers [ J ]. Thromb Res, 2012, 130 (Suppl 1 ) : 12-15.
  • 3Tedgui A, Mallat Z. Cytokines in atherosclerosis : pathogenic and regulatory pathways [J], Physiol Rev, 2006,86(2) :515-581.
  • 4Gensini GG. A more meaningful scoring system for deter- mining the severity of coronary heart disease [J]. Am J Cardiol, 1983,51 (3) : 606.
  • 5Shevchenko AO,Slesareva Iu S,Shevchenko OP. Labora- tory diagnosis of atherosclerotic plaque damage in pa- tients with coronary heart disease:PAPP-A (a review of literature) [ J ]. Klin Lab Diagn, 2011,5 ( 1 ) : 3-10.
  • 6Olson KA, Fett JW, French TC, et al. Angiogenin antago- nists prevent tumor growth in vivo[J]. Proc Natl Acad Sci U S A, 1995,92(2) :442-446.
  • 7Silha JV,Krsek M,Hana V,et al. The effects of growth hormone status on circulating levels of vascular growth factors[J]. Clin Endocrinol (Oxf) ,2005,63( 1 ) :79-86.
  • 8Tello-Montoliu A,Marin F,Patel J,et al. Plasma angio- genin levels in acute coronary syndromes:implications for prognosis[J]. Eur Heart J,2007,28(24):3006-3011.
  • 9Krecki R, Krzeminska-Pakula M, Peruga JZ, et al. Elevat- ed resistin opposed to adiponectin or angiogenin plasma levels as a strong,independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up[J]. Med Sci Monit,2011, 17( 1 ) : CR26-CR32.
  • 10Cybulsky MI,Iiyama K,Li H,et al. A major role for VCAM-1,but not ICAM-1,in early atherosclerosis [J]. J Clin Invest,2001,107(10) : 1255-1262.

共引文献9

同被引文献67

引证文献8

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部